CONTAGEM DE MESÓFILOS E PSICROTRÓFICOS EM AMOSTRAS DE LEITE PASTEURIZADO E UHT

Food of animal or vegetable ori gin can serve various pathogenic microorganisms. The food of anima l origin, milk const i tutes an important medium of culture for the development of a large number of microorgani sms. It is also susceptible to tamperi ng and contamina tion, which makes qual ity monitoring a necessi ty, to ensur e a n a dequat e final produ ct both t o the consumer and industry. This st udy aimed to determine the level of contaminat ion of pasteurized and UHT milk by psychrotrophic and mesophilic, Staphylococcus sp. and Bacillus cereus. Were analyzed 9 samples of pasteur ized and 9 samples of UHT milk, randomly purchased from supermarket, totaling 18 samples. The UHT milk showed no contamina t ion by microorga ni sms, pasteu r ized milk was contamina ted by mesophiles, and in three of the samples exceeded the amou nt al lowed by l aw; and a high contamination by Staphylococcus sp. (until 6,11 log10 UFC/mL) and Bacillus cereus (until 5,60 log10 UFC/mL). The high count s of mesophilic serve to aler t publ ic hea lth au thor i t ies to the potentia l r isk of cert ain ba cteria t hat produce toxins causing outbreaks.Os alimentos de origem animal, como o leite, constituem um importante meio de cultura para o desenvolvimento de micro-organismos patogênicos. Por ser passível de adulterações e contaminações é necessário o monitoramento, a fim de assegurar ao consumidor e a indústria um produto final de boa qualidade. O objetivo deste trabalho foi determinar o nível de contaminação por bactérias mesófilas e psicrotróficas, Staphylococcus sp. e Bacillus cereus em leite pasteurizado e UHT comercializados no município de Bandeirantes, Paraná. Foram analisadas 9 amostras de leite pasteurizados e 9 de UHT, adquiridas aleatoriamente do comércio local, totalizando 18 amostras. O leite UHT não apresentou contaminação por micro-organismos. Já o leite pasteurizado todas as amostras apresentaram contaminação por mesófilos aeróbios, sendo que três amostras ultrapassaram o valor permitido pela Instrução Normativa N°51, além da elevada contaminação por Staphylococcus coagulase positiva (até 6,11 log10 UFC/mL) e Bacillus cereus (até 5,60 log10 UFC/mL). A alta contagem de mesófilos aeróbios serve de alerta às autoridades de saúde pública para o risco potencial de determinados micro-organismos produtores de toxinas causarem intoxicações alimentares

Atividade antibacteriana do extrato hidroalcoólico de Punica granatum Linn. sobre Staphylococcus spp. isolados de leite bovino

Bovine mastitis is characterized by inflammation of the mammary gland, usually in response to bacterial infection, affecting qualitatively and quantitatively milk production. This study aimed to determine the antibacterial activity in vitro of the hydroalcoholic extract of the bark of the pomegranate on bacteria isolated from bovine milk. The colonies of Staphylococcus spp. were resuspended in 6 MacFarland scale and adjusted its concentration by UV visible spectrophotometry at a concentration of 106ml-1. The extracts were evaluated in quintuplicate in seven concentrations: from 4 up to 0.0625mg.mL-1. The sensitivity of microbial isolates was determined using the disk diffusion and the results that showed inhibition halos corresponding to values from 15mm were considered susceptible. The results were evaluated by ANOVA, Tukey test 5% using the SISVAR 5.3-DEX/UFLA. Additionally the extract was assessed as for the antioxidant activity, content of phenols and total flavonoids. The extract was diluted into seven concentrations: 25-1.000µg.mL-1, and evaluated in triplicate. The bacterial growth was inhibited starting from the concentration of 4 mg.mL-1 and antioxidant activity was observed from 50µg.mL-1, with values corresponding to 4.62% reaching the plateau of 64.90% at a concentration of 500µg.mL-1. In evaluating the radical scavenging activity, using the free radical DPPH, the extract demonstrated antioxidant activity (IC50%= 378.80µg/mL). However it has not been possible to correlate the antioxidant activity with the levels of phenols and flavonoids. Perhaps the presence of other substances alkaloids and tannins present in the extracts may have been responsible for the antioxidant activity found. It was concluded that the hydroalcoholic extract of Punica granatum Linn. has antimicrobial activity against Staphylococcus spp., demonstrating potential benefit for the control of bovine mastitis.Mastite bovina é caraterizada por inflamação da glândula mamária, geralmente em resposta à infecção bacteriana, compromete quali-quantitativamente a produção leiteira. Este estudo objetivou verificar a atividade antibacteriana in vitro do extrato hidroalcoólico da casca da romã sobre bactérias isoladas de leite bovino. As colônias de Staphylococcus spp. foram ressuspendidas a escala 6 de MacFarland e ajustada a sua concentração por espectrofotometria UV visível na concentração de 10 mL-1. Os extratos foram avaliados em quintuplicata, em sete concentrações: de 4mg mL-1 até 0,0625 mg.mL-1. A sensibilidade dos isolados microbianos foi determinada utilizando o teste de difusão em disco e os resultados que apresentaram zonas de inibição correspondentes a valores a partir de 15 mm, foram considerados sensíveis. Os resultados foram avaliados pelo método ANOVA, teste de Tukey 5%, utilizando o SISVAR 5.3 -DEX/UFLA. Adicionalmente o extrato foi avaliado quanto à atividade antioxidante, teores de fenóis e flavonoides totais. Para tanto o extrato foi diluído em sete concentrações: de 25 a 1000µg.mL-1, e avaliado em triplicata. O crescimento bacteriano foi inibido a partir da concentração de 4mg.mL-1 e a ação antioxidante foi verificada a partir de 50µg.mL-1, com valores correspondentes a 4.62%, atingindo platô de 64,90% na concentração de 500µg.mL-1. Na avaliação da atividade captadora de radicais, empregando o radical livre DPPH, o extrato demonstrou atividade antioxidante (IC50%= 378,80µg/mL). Porém, não foi possível correlacionar a atividade antioxidante aos teores de fenóis e flavonoides. Talvez a presença de outras substâncias alcaloides e taninos presentes no extrato, possam ter sido as responsáveis pela atividade antioxidante encontrada. Conclui-se que o extrato hidroalcoólico de Punica granatum Linn. apresenta atividade antimicrobiana contra Staphylococcus spp., demonstrando potencial benefício para o controle da mastite bovina.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq

A genetic algorithm for a global optimization problem arising in the detection of gravitational waves

Global optimization, Genetic algorithm, Detection of gravitational waves,

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

© 2020 Elsevier Ltd. All rights reserved.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran.info:eu-repo/semantics/publishedVersio

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)